Sunovion (United Kingdom)

Sunovion (United Kingdom)

On July 1, 2023, Sunovion Pharmaceuticals Inc. became part of Sumitomo Pharma America, Inc., a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need spanning psychiatry and neurology, oncology, urology, women's health, rare disease, and cell and gene therapies. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Sunovion (United Kingdom), United Kingdom, covering academic research published from 2000 to 2023. Read More.


Open Access Percentage

44%


Total
Publications

104


Total Open
Publications

46


Total
Citations

1K


Open Access
Percentage

44%


Total
Publications

104


Total Open
Publications

46


Total
Citations

1K

Wikipedia

Website

download

Breakdown

12% 20% 12% 56%

Publisher Open

12%

Both

20%

Other Platform Open

12%

Closed

56%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

024681012141618Total Publications
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023

Open

Closed

Publisher Open

12%OA Journal

OA Journal 12%

4

Hybrid 33%

11

No Guarantees 55%

18

Other Platform Open

Domain 82%

28

Preprint 9%

3

Public 9%

3

Institution 6%

2

Other Internet 6%

2

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
28
Europe PMC
Domain
12
Semantic Scholar
Public
3
Unknown Repository
Other Internet
2
University of Leeds, The University of Sheffield, University of York - White Rose Research Online
Institution
2
Research Square
Preprint
1
Queen Mary University of London - Queen Mary Research Online
Institution
1
Imperial College London - Spiral
Institution
1
bioRxiv
Preprint
1
arXiv
Preprint
1
1 / 1

Data updated 25 January 2024

Share

Share

Share